Aardvark Therapeutics Common Stock Statistics
Share Statistics
Aardvark Therapeutics Common Stock has 21.7M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 21.7M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,176 |
| FTD / Avg. Volume | 1.8% |
Short Selling Information
The latest short interest is 319.12K, so 1.49% of the outstanding
shares have been sold short.
| Short Interest | 319.12K |
| Short % of Shares Out | 1.49% |
| Short % of Float | 2.51% |
| Short Ratio (days to cover) | 5.19 |
Valuation Ratios
The PE ratio is -8.97 and the forward
PE ratio is null.
Aardvark Therapeutics Common Stock's PEG ratio is
0.09.
| PE Ratio | -8.97 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 2.56 |
| P/FCF Ratio | -10.15 |
| PEG Ratio | 0.09 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aardvark Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.05,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.05 |
| Quick Ratio | 15.05 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-935,818.18 |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Aardvark Therapeutics Common Stock's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 9.2 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.31 |
| Average Volume (20 Days) | 120,624 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.79M |
| Net Income | -20.59M |
| EBITDA | -22.65M |
| EBIT | -22.67M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 61.64M in cash and 779K in
debt, giving a net cash position of 60.86M.
| Cash & Cash Equivalents | 61.64M |
| Total Debt | 779K |
| Net Cash | 60.86M |
| Retained Earnings | -58.33M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -18.09M
and capital expenditures -109K, giving a free cash flow of -18.2M.
| Operating Cash Flow | -18.09M |
| Capital Expenditures | -109K |
| Free Cash Flow | -18.2M |
| FCF Per Share | -1.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
